| Authors: |
Gehlert CL; Division of Antibody-Based Immunotherapy, Department of Internal Medicine II, Kiel University and University Hospital Schleswig-Holstein, Campus Kiel, Germany., Krohn S; Division of Antibody-Based Immunotherapy, Department of Internal Medicine II, Kiel University and University Hospital Schleswig-Holstein, Campus Kiel, Germany., Winterberg D; Division of Antibody-Based Immunotherapy, Department of Internal Medicine II, Kiel University and University Hospital Schleswig-Holstein, Campus Kiel, Germany., Boje AS; Division of Antibody-Based Immunotherapy, Department of Internal Medicine II, Kiel University and University Hospital Schleswig-Holstein, Campus Kiel, Germany., Theocharis T; Division of Antibody-Based Immunotherapy, Department of Internal Medicine II, Kiel University and University Hospital Schleswig-Holstein, Campus Kiel, Germany., Jochimsen A; Division of Antibody-Based Immunotherapy, Department of Internal Medicine II, Kiel University and University Hospital Schleswig-Holstein, Campus Kiel, Germany., Lustig M; Division of Stem Cell Transplantation and Cellular Immunotherapy Department of Internal Medicine II, Kiel University and University Hospital Schleswig-Holstein, Campus Kiel, Germany., Valerius T; Division of Stem Cell Transplantation and Cellular Immunotherapy Department of Internal Medicine II, Kiel University and University Hospital Schleswig-Holstein, Campus Kiel, Germany., Kellner C; Division of Transfusion Medicine, Cell Therapeutics and Haemostaseology, University Hospital, LMU Munich, Munich, Germany., Klausz K; Division of Antibody-Based Immunotherapy, Department of Internal Medicine II, Kiel University and University Hospital Schleswig-Holstein, Campus Kiel, Germany., Peipp M; Division of Antibody-Based Immunotherapy, Department of Internal Medicine II, Kiel University and University Hospital Schleswig-Holstein, Campus Kiel, Germany. m.peipp@med2.uni-kiel.de. |
